Comparing Cost of Revenue Efficiency: Jazz Pharmaceuticals plc vs Bausch Health Companies Inc.

Cost Efficiency Showdown: Jazz vs. Bausch Over a Decade

__timestampBausch Health Companies Inc.Jazz Pharmaceuticals plc
Wednesday, January 1, 20142254600000117418000
Thursday, January 1, 20152645000000102526000
Friday, January 1, 20162611000000105386000
Sunday, January 1, 20172548000000110188000
Monday, January 1, 20182351000000121544000
Tuesday, January 1, 20192350000000127930000
Wednesday, January 1, 20202249000000148917000
Friday, January 1, 20212394000000440760000
Saturday, January 1, 20222364000000540517000
Sunday, January 1, 20232559000000435577000
Loading chart...

In pursuit of knowledge

A Decade of Cost Efficiency: Jazz Pharmaceuticals vs. Bausch Health

In the competitive landscape of pharmaceuticals, cost efficiency is a critical metric. Over the past decade, Jazz Pharmaceuticals plc and Bausch Health Companies Inc. have demonstrated contrasting approaches to managing their cost of revenue. From 2014 to 2023, Bausch Health consistently maintained a higher cost of revenue, averaging around $2.4 billion annually. In contrast, Jazz Pharmaceuticals operated with a significantly leaner cost structure, averaging approximately $225 million per year.

Interestingly, Jazz Pharmaceuticals showed a remarkable increase in cost efficiency, with a 370% rise in cost of revenue from 2014 to 2022, peaking in 2022. Meanwhile, Bausch Health's cost of revenue remained relatively stable, with minor fluctuations, indicating a steady operational strategy. This comparison highlights the diverse strategies in cost management within the pharmaceutical industry, offering insights into how companies balance growth and efficiency.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025